Pharma & Biotech News , from our Global Correspondents
Refine Search
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Pharmaceutical
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
Generics
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
Pharmaceutical
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Generics
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
Generics
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Pharmaceutical
Complex regional pain syndrome (CRPS) is a chronic and potentially debilitating neuropathic pain condition that typically affects an extremity, such as an arm or leg.1 22 November 2023
Biosimilars
Russian pharmaceutical companies are eyeing expanding in the United Arab Emirates (UAE) by launching production of their drugs and establishing their manufacturing facilities in the local market. 22 November 2023
Biosimilars
Indian pharmaceutical company Jodas Expoim is experiencing serious problems with the construction of its first enterprise in the Russian Federation. 21 November 2023
Generics
Even as India's drug pricing authority, the National Pharmaceutical Pricing Authority (NPPA) last week brought 33 fixed-dose combination (FDC) drugs under its price regulation, in an initiative to make these drugs more cost-effective, a recent comprehensive analysis reveals a concerning trend, that the Indian government's efforts to eliminate centrally unapproved and banned antibiotic FDC drugs have experienced limited success, reports The Pharma Letter’s India correspondent. 20 November 2023
Generics
The Russian Medical Research Company, which is a subsidiary of Swiss firm Genfa Global, is considering the production of Trilexa, which is a generic of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), a drug for treatment of cystic fibrosis from the USA’s Vertex Pharmaceuticals, The Pharma Letter’s local correspond reports. 15 November 2023
Pharmaceutical
Insulin sales in Russia have hit a five-year low, as local patients and government agencies have stopped buying the product for future use, reports The Pharma Letter’s local correspondent. 14 November 2023
Generics
German pharmaceutical major Bayer has refused compensation of more than 400 million roubles ($4.3 million) from Russian Nativa (renamed Spectrum) for the use of patents on the anticancer drug Nexavar (sorafenib), reports The Pharma Letter’s local correspondent. 9 November 2023
Generics
Hungarian drugmaker Gedeon Richter has begun supplying generics of foreign drugs for diabetics to Russia – in a move to take the share of those global drugmakers that have left Russia, reports The Pharma Letter’s local correspondent. 8 November 2023
Biosimilars
Indian pharmaceutical companies are demonstrating a growing commitment to advancing cancer treatment through substantial investments in biologics. 31 October 2023
Pharmaceutical
Russian pharmaceutical manufacturers have increased the number of clinical trials that are conducted in the domestic market as part of their efforts of import substitution, The Pharma Letter’s local correspondent reports. 31 October 2023
Generics
The Slovenian generics drugmaker KRKA has achieved a rehearing of its case in the Russian Presidium of the Intellectual Rights Court (IPR), which could lead to the revocation of US pharma major AstraZeneca's patent for dapagliflozin - a drug for the treatment of type 2 diabetes, reports The Pharma Letter’s local correspondent. 30 October 2023
Pharmaceutical
In October 2022, the US Food and Drug Administration (FDA) released its “Multiple Endpoints in Clinical Trials” document to provide guidance for drug sponsors and other stakeholders regarding best practices in assessment methodologies for medications. 24 October 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
The first generic version of the popular drug for controlling glucose levels, Ozempic (semaglutide), which is produced by the Danish diabetes care giant Novo Nordisk, has been registered in Russia by a local drugmaker, the Pharma Letter’s local correspondent reports. 18 October 2023
Pharmaceutical
October marks the annual Rett Syndrome Awareness Month, a time to examine the support and research being afforded to advance pharmacological treatments for this rare condition. 18 October 2023
Pharmaceutical
Despite statements from international pharmaceutical companies about the suspension of new clinical trials in Russia after February 24, 2022 invasion of Ukraine, the Anglo-Swedish drug major AstraZeneca will conduct a study of a new drug for the prevention of COVID-19 in Russia, reports The Pharma Letter’s local correspondent. 18 October 2023
Biotechnology
One big challenge for pharma companies doing cross-border businesses in China and the USA is the respective cybersecurity law imposed by the two countries. 12 October 2023
Pharmaceutical
Russia is losing its positions in the global drug export market due to difficulties in settlements with foreign partners, caused by sanctions imposed against the country, The Pharma Letter’s local correspondent reports. 10 October 2023
Pharmaceutical
The situation with the availability of modern, original drugs continues to deteriorate in Russia, which is mainly due to ever-tightening sanctions against the country and its growing isolation in the international arena, reports The Pharma Letter’s local correspondent. 9 October 2023
Pharmaceutical
Caught up in the geopolitical tension between China and the West, western pharma multi-national corporations (MNCs) are increasingly cautious about investing in China. 5 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze